GGrantIndex
← Search

Molecular Cytogenetics

$124,471P30FY2008CANIH

Ohio State University, Columbus OH

Investigators

Linked publications, trials & patents

Trial NCT04662645Trial NCT04602026Trial NCT04567706Trial NCT04454086Trial NCT04439006Trial NCT04329962Trial NCT04269837Trial NCT04267874Trial NCT04233567Trial NCT04229381Trial NCT04220684Trial NCT04205903Trial NCT04205240Trial NCT04205071Trial NCT04164069Trial NCT04140513Trial NCT04120454Trial NCT04116970Trial NCT04115163Trial NCT04063410Trial NCT04049539Trial NCT04032106Trial NCT03975231Trial NCT03943342Trial NCT03892044Trial NCT03868423Trial NCT03858855Trial NCT03824327Trial NCT03798639Trial NCT03786354Trial NCT03749018Trial NCT03728361Trial NCT03719092Trial NCT03715959Trial NCT03711890Trial NCT03691350Trial NCT03665675Trial NCT03656835Trial NCT03654638Trial NCT03631641Trial NCT03611205Trial NCT03583424Trial NCT03568526Trial NCT03537599Trial NCT03532581Trial NCT03525925Trial NCT03513562Trial NCT03463460Trial NCT03460483Trial NCT03447808Trial NCT03409432Trial NCT03372720Trial NCT03333746Trial NCT03328936Trial NCT03307044Trial NCT03287453Trial NCT02960100Trial NCT02950220Trial NCT02942524Trial NCT02940301Trial NCT02927899Trial NCT02835755Trial NCT02831582Trial NCT02812693Trial NCT02795104Trial NCT02791737Trial NCT02760030Trial NCT02439255Trial NCT02303392Trial NCT02101944Trial NCT02015117Trial NCT01964924Trial NCT01955499Trial NCT01861314Trial NCT01841723Trial NCT01811212Trial NCT01533194Trial NCT01519414Trial NCT01515176Trial NCT01468896Trial NCT01425879Trial NCT01351896Trial NCT01281124Trial NCT01280058Trial NCT01254617Trial NCT01254578Trial NCT01251874Trial NCT01249430Trial NCT01238133Trial NCT01132586Trial NCT01130506Trial NCT01129193Trial NCT01126502Trial NCT01076556Trial NCT01017640Trial NCT00735930Trial NCT00703300Trial NCT00602277Trial NCT00563290Trial NCT00499473

Abstract

The Molecular Cytogenetics Shared Resource (MCSR) has been in development over the last three years and was formally established as a shared resource in September 2003 to provide a wide range of cytogenetic services and investigations to the OSUCCC research community. It provides state-of-the-art molecular cytogenetic technology as well as classical banded metaphase cytogenetics. Services include metaphase karyotyping of human and mouse tissue, fluorescence in situ hybridization (FISH) using many different types of probes and tissues and multicolor spectral karyotyping (SKY). Dr. Heerema, Director of the Resource, brings a wealth of experience to the MCSR with over 25 years of experience in cytogenetics and over 135 publications. Dr. Mrozek, Associate Director of the Resource, has over 20 years of experience in cytogenetics and over 80 publications. Various specimen sources, such as human and mouse cell lines and tumor samples, paraffin embedded tissues and bone marrow or blood smears are studied, dependent on the purpose of the investigation. Services accommodate different stages of sample preparation from processing fresh tissues to preparing slides from fixed cell suspensions. Probes for FISH studies include both commercially available probes and probes developed by the MCSR. Probe development offerings include growth, amplification and labeling of the probes with different fluorophores available. The types of probes include unique-sequence DNA probes, BACs, PACs and YACs. The MCSR has been widely used by the OSUCCC research community. The projects vary from karyotyping cell lines to development of FISH probes (including probes specific for canine chromosomes), identification of appropriate samples to test the probes and performing FISH on cell lines and archived specimens. From inception to date, 15 OSUCCC members have used the MCSR for 24 different projects representing all six OSUCCC programs and requiring over 2,000 hours of usage. Tools used have included SKY analysis of cell lines and patient samples, G-banded karyotyping of mouse and human tumors and various cell lines, FISH using several different probes and tissues for hybridization as well as development and labeling of some of the probes. An additional 22 projects have been identified for future service. Maintenance of high-standards, establishment and proper use of controls and control values and careful monitoring of all phases of investigation assure quality. It is expected that future use of the MCSR will continue to be extensive, as investigators have indicated continuing need for the services offered.

View original record on NIH RePORTER →